BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27468851)

  • 1. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
    Kim TK; Xu ML; Podoltsev NA; Prebet T; Barbarotta L; Amin K; Kasberg S; Roche K; Stahl M; Gore SD; Zeidan AM
    Ann Hematol; 2016 Oct; 95(11):1895-8. PubMed ID: 27468851
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
    Gururangan S; Horner M; Rodman JH; Marina NM
    Med Pediatr Oncol; 1994; 22(6):414-6. PubMed ID: 8152404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
    Soslow RA; Davis RE; Warnke RA; Cleary ML; Kamel OW
    Blood; 1996 Jun; 87(12):5207-12. PubMed ID: 8652834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia.
    Thakral B; Khoury JD
    Blood; 2016 Nov; 128(20):2475. PubMed ID: 27856472
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
    Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
    Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
    Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
    Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
    Innes A; May PC; Pavlů J; Bain BJ
    Am J Hematol; 2012 Apr; 87(4):412. PubMed ID: 21953481
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
    Layden BT; Joseph M; Tallman MS; Platanias LC
    Acta Haematol; 2007; 118(4):242-3. PubMed ID: 18087146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
    Dunphy CH; Kitchen S; Saravia O; Velasquez WS
    Am J Hematol; 1996 Jan; 51(1):85-9. PubMed ID: 8571944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
    Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
    Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
    Bravo-Perez C; Pajares I; Muiña B; Escobar H; Amigo ML; Garcia-Malo MD; Garcia J; Rodriguez-Pinilla SM; Piris MA; Ortuño FJ
    Ann Hematol; 2020 Feb; 99(2):391-393. PubMed ID: 31858188
    [No Abstract]   [Full Text] [Related]  

  • 16. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusion of anti-CD10 monoclonal antibody (J5) following ablative chemotherapy in a patient with refractory pre-B acute lymphoblastic leukemia.
    Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Presno-Bernal M; Alvarez-Amaya C
    Rev Invest Clin; 1991; 43(3):259-63. PubMed ID: 1840161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Jorgensen JL; Cortes J; Faderl S; Garcia-Manero G; Verstovsek S; Koller C; Pierce S; Huh Y; Wierda W; Keating MJ; Kantarjian HM
    Blood; 2009 Jun; 113(25):6330-7. PubMed ID: 18703706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.